Company Team Projects Media Contact

An innovative therapeutic approach to bacterial infection

Combioxin develops innovative anti-virulence treatments for serious bacterial infections, including those caused by antibiotic-resistant strains. The lead candidate, CAL02, is a first-in-class, clinical-stage non-antibiotic liposomal drug that neutralizes bacterial toxins, protects against infection severity and complications, and improves antibiotic efficacy.



Combioxin announces oral presentation of results from the CAL02-001 clinical trial at ECCMID 2017

Discover Combioxin's CAL02 against bacterial resistance broadcasted on 3sat - 15/02/2017